Response rate in patients with high-risk cytogenetics: t(4;14), t(14;16), del 17p
| . | QT + V, n = 23 . | TD, n = 22 . | VTD, n = 23 . |
|---|---|---|---|
| CR, % | 22* | 0* | 35* |
| VGPR, % | 9 | 27 | 22 |
| PR, % | 30 | 18 | 22 |
| SD, % | 13 | 14 | 9 |
| PD, % | 26† | 41† | 3† |
| Early deaths, % | 0 | 0 | 9 |
| . | QT + V, n = 23 . | TD, n = 22 . | VTD, n = 23 . |
|---|---|---|---|
| CR, % | 22* | 0* | 35* |
| VGPR, % | 9 | 27 | 22 |
| PR, % | 30 | 18 | 22 |
| SD, % | 13 | 14 | 9 |
| PD, % | 26† | 41† | 3† |
| Early deaths, % | 0 | 0 | 9 |
QT + V indicates chemotherapy + bortezomib; TD, thalidomide/dexamethasone; VTD, bortezomib/thalidomide/dexamethasone; CR, complete response; VGPR, very good partial response; PR, partial response; SD, stable disease; and PD, progressive disease.
VTD vs TD, P = .002; VTD vs QT + V, P = .02.
VTD vs TD, P = .004; VTD vs QT + V, P = .04.